Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash & Current Investments (2023 - 2025)

Compass Therapeutics' Cash & Current Investments history spans 3 years, with the latest figure at $208.9 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 64.12% year-over-year to $208.9 million; the TTM value through Dec 2025 reached $208.9 million, up 64.12%, while the annual FY2025 figure was $208.9 million, 64.12% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $208.9 million at Compass Therapeutics, down from $219.9 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $219.9 million in Q3 2025 and bottomed at $101.5 million in Q2 2025.
  • The 3-year median for Cash & Current Investments is $158.1 million (2023), against an average of $157.4 million.
  • The largest YoY upside for Cash & Current Investments was 64.12% in 2025 against a maximum downside of 35.7% in 2025.
  • A 3-year view of Cash & Current Investments shows it stood at $152.5 million in 2023, then fell by 16.51% to $127.3 million in 2024, then skyrocketed by 64.12% to $208.9 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Cash & Current Investments are $208.9 million (Q4 2025), $219.9 million (Q3 2025), and $101.5 million (Q2 2025).